Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, et al. | Cell Metabolism | 2016 | Evidence: limited

Plain-language summary

Published 2016 in Cell Metabolism, this work by Mills KF and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

12-month NMN administration suppressed age-associated weight gain in mice
Improved energy metabolism, insulin sensitivity, plasma lipid profile, mitochondrial function
Foundation animal study cited in most NMN human trial rationales

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions, with secondary relevance to benefits. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index